Loading…
Forte Biosciences, Inc. is projected to rise to $103.61 by 2027, a +35% move from its current price of $76.60. FBRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $71.42 | $76.69 | $82.34 | +0.11% |
| Aug 3 | $69.42 | $76.77 | $84.90 | +0.23% |
| Aug 4 | $67.95 | $76.86 | $86.94 | +0.34% |
| Aug 5 | $66.74 | $76.95 | $88.71 | +0.45% |
| Aug 6 | $65.70 | $77.03 | $90.32 | +0.56% |
| Aug 7 | $64.78 | $77.12 | $91.80 | +0.68% |
| Aug 8 | $63.96 | $77.21 | $93.20 | +0.79% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $63.96 | $77.21 | $93.20 | +0.79% |
| Week 2 | $59.63 | $77.82 | $101.55 | +1.59% |
| Week 3 | $56.61 | $78.43 | $108.66 | +2.39% |
| Week 4 | $54.25 | $79.05 | $115.19 | +3.20% |
| Week 5 | $52.30 | $79.67 | $121.38 | +4.01% |
| Week 6 | $50.64 | $80.30 | $127.35 | +4.83% |
| Week 7 | $49.19 | $80.94 | $133.19 | +5.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes.
Forte Biosciences is headquartered in Dallas, Texas.
The company is categorized in Healthcare and focuses on developing therapies for autoimmune conditions. Its core description places it within the clinical-stage biopharma space, with a Dallas base of operations and a focus on FB-102 as a key candidate for autoimmune indications.
Forte Biosciences, Inc. (FBRX) is a healthcare stock with a current price of $76.50 and a market capitalization of $1.57B. It is ranked 2107 in market listings.
The price outlook shows a long-run bullish trajectory in the forecast, beginning with a 2026 average price of $76.50 and expanding in subsequent years, reaching a 2030 average of $121.17 and continuing to $613.99 by 2050. The forecast also presents a wide price range for 2026 (min $15.67, max $126.16) and a succession of rising averages through 2030–2050, accompanied by positive sentiment and increasing ROI figures. The 30-day price context is wide, with a range of $45.37 to $129.00, reflecting notable near-term volatility.
The stock is characterized by high implied volatility, with an annualized volatility of 200%. The forecast includes a sequence of bullish sentiment entries from 2027 onward, contrasting the neutral stance for 2026.
A major floor 79.5% below — a decisive break under it would weaken the trend.
The nearest floor, 76.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.5% away) — a breakout level to watch.
A major ceiling 51.8% above — clearing it would confirm fresh momentum.
Key FBRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FBRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $76.65 | Sell | $73.68 | Buy |
| MA 10 | $65.26 | Buy | $66.48 | Buy |
| MA 20 | $51.09 | Buy | $54.99 | Buy |
| MA 50 | $31.82 | Buy | $39.93 | Buy |
| MA 100 | $29.53 | Buy | $32.87 | Buy |
| MA 200 | $26.41 | Buy | $27.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 84.78 | Sell |
| Stoch RSI (14) | 71.00 | Neutral |
| CCI (20) | 116.76 | Buy |
| Williams %R (14) | -1.12 | Info |
| MACD (12,26,9) | 2.62 | Buy |
| ROC (12) | 73.50 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 98.88 | Sell |
| TRIX (15) | 5.08 | Buy |
| Awesome (5,34) | 38.73 | Buy |
| Ultimate (7,14,28) | 83.46 | Sell |
| Momentum (10) | 27.74 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 82.33 | Sell |
| ADX (14) | 55.10 | Buy |
| ATR (14) | 2.99 | Info |
Near-term technicals show a bullish tilt with a strong momentum backdrop. The sentiment is BULLISH and the RSI(14) is 90, indicating overbought conditions on a short horizon.
Key moving averages place the stock in a positive momentum frame: SMA50 is $26.85 and SMA200 is $24.97. Support sits at $17.15 and resistance at $76.50, with a 30-day price window of $45.37 to $129.00. This combination suggests upside potential within a broad trading range, alongside elevated volatility as reflected by the market’s price action.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.67 | $76.60 | $126.51 | 0% | Neutral | |
| $75.45 | $103.61 | $153.74 | +35% | Bullish | |
| $81.88 | $119.56 | $189.29 | +56% | Bullish | |
| $77.90 | $119.87 | $199.35 | +56% | Bullish | |
| $75.87 | $122.42 | $212.02 | +60% | Bullish | |
| $78.24 | $131.96 | $236.65 | +72% | Bullish | |
| $101.51 | $178.60 | $330.30 | +133% | Bullish | |
| $129.24 | $236.81 | $450.21 | +209% | Bullish | |
| $125.53 | $239.28 | $466.46 | +212% | Bullish | |
| $120.02 | $237.80 | $474.42 | +210% | Bullish | |
| $181.95 | $404.34 | $886.80 | +428% | Bullish | |
| $279.59 | $621.31 | $1,429.00 | +711% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $15.67 | $76.60 | $103.56 | +0.00% |
| September 2026 | $69.20 | $84.24 | $107.06 | +9.97% |
| October 2026 | $68.77 | $84.87 | $110.02 | +0.75% |
| November 2026 | $73.27 | $91.44 | $120.42 | +7.74% |
| December 2026 | $75.10 | $94.70 | $126.51 | +3.57% |
Click any year to see its month-by-month FBRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Forte Biosciences, Inc.'s 2026 outlook centres on $76.60, within a $15.67 to $126.51 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, FBRX could reach as high as $153.74, with a base case around $103.61 and support toward $75.45 — roughly +35% from $76.60. Momentum favours further upside here.
Expect FBRX to range from $81.88 to $189.29 through 2028. The $119.56 average target implies a +56% move from current prices. That is up +15% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The FBRX price prediction for 2029 points to an average of $119.87 (low $77.90, high $199.35) — a potential gain of +56% on today's $76.60. Momentum favours further upside here.
In 2030, FBRX is projected to trade between $75.87 and $212.02, averaging $122.42 — a potential gain of +60% from today's $76.60. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Forte Biosciences, Inc.'s 2031 outlook centres on $131.96, within a $78.24 to $236.65 range. That is up +8% on the projected 2030 average. That marks a +72% change versus current levels. Momentum favours further upside here.
By 2032, FBRX could reach as high as $330.30, with a base case around $178.60 and support toward $101.51 — roughly +133% from $76.60. Buyers look set to stay in control over this stretch.
Expect FBRX to range from $129.24 to $450.21 through 2033. The $236.81 average target implies a +209% move from current prices. That is up +33% on the projected 2032 average. Momentum favours further upside here.
The FBRX price prediction for 2034 points to an average of $239.28 (low $125.53, high $466.46) — a potential gain of +212% on today's $76.60. Buyers look set to stay in control over this stretch.
In 2035, FBRX is projected to trade between $120.02 and $474.42, averaging $237.80 — a potential gain of +210% from today's $76.60. That is -1% versus the projected 2034 average. Momentum favours further upside here.
Forte Biosciences, Inc.'s 2040 outlook centres on $404.34, within a $181.95 to $886.80 range. That is up +70% on the projected 2035 average. That marks a +428% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, FBRX could reach as high as $1,429.00, with a base case around $621.31 and support toward $279.59 — roughly +711% from $76.60. Momentum favours further upside here.
Investing $1,000 in FBRX today (≈ 13.05483 FBRX) could be worth
$8,111.05
+$7,111.05 (+711%) by 2050 · US Dollar
Based on the average projected FBRX price of $621.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FBRXwould be worth at today's price.
$1,000 invested in FBRX on Jul 31, 2025 (≈ 100.200405 FBRX) would be worth
$7,675.35
+$6,675.35 (+667.5%) today · 7.68× · US Dollar
Based on a FBRX entry price of $9.98 vs. today's $76.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $54.78 | $1,398.32 | +39.8% |
| 1 month ago | $21.32 | $3,592.87 | +259.3% |
| 3 months ago | $28.19 | $2,717.28 | +171.7% |
| 6 months ago | $34.49 | $2,220.93 | +122.1% |
| 1 year ago | $9.98 | $7,675.35 | +667.5% |
| All time (5.0y) ago | $760 | $100.79 | -89.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FBRX forecast.
Our base-case forecast reaches $150.00 around 2032.
Implied market cap at $150.00: $3.07B
The multi-year forecast portrays a persistent bullish trajectory, with average prices rising across the horizon and substantial upside potential. By 2030 the expected average price is $121.17 with an ROI of 58.4% and bullish sentiment. In the intervening years, 2027 shows an average of $102.81 and 2028 an average of $120.56, continuing the trend toward higher values.
Looking further out, 2040 is forecast to average $406.68 with an ROI of 431.6%, and 2050 is forecast to average $613.99 with an ROI of 702.6%, both with bullish sentiment. The max prices in those years indicate meaningful upside, up to $209.94 in 2030 and up to $1,412.17 by 2050, underscoring the potential for substantial appreciation alongside the projected long-run trend.
These figures reflect estimates of future pricing and are not guarantees; they hinge on multiple variables that can affect a clinical-stage biopharmaceutical company’s performance and market perception. Investors should weigh the bullish forecasts against inherent trial, regulatory, and commercialization risks.
Tap a question to reveal the answer.
The average forecast price in 2030 is $121.17, with a min of $75.06 and a max of $209.94, and an estimated ROI of 58.4% with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with increasing average prices (e.g., $102.81 in 2027, $121.17 in 2030, $406.68 in 2040, and $613.99 in 2050) and positive ROI in those years (e.g., 34.4% in 2027, 57.6% in 2028, 55.5% in 2029, 58.4% in 2030, 431.6% in 2040, 702.6% in 2050). Note that these are forecasts and not guarantees.
Yes. The 2030 forecast max is $209.94, which exceeds $200.
Current price is $76.50 and the market capitalization is $1.57B.
RSI(14) is 90 and the sentiment is BULLISH. The 30-day range is $45.37 to $129.00. The moving averages are SMA50 at $26.85 and SMA200 at $24.97. The stock has support at $17.15 and resistance at $76.50.
Forte Biosciences, Inc. Community Discussion
0Share your Forte Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.